NewAmsterdam Pharma (NASDAQ:NAMS) Short Interest Update

NewAmsterdam Pharma (NASDAQ:NAMS) saw a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 4,340,000 shares, a growth of 42.8% from the February 28th total of 3,040,000 shares. Currently, 7.5% of the shares of the stock are short sold. Based on an average trading volume of 843,800 shares, the days-to-cover ratio is currently 5.1 days.

Analyst Ratings Changes

Several brokerages have recently commented on NAMS. Royal Bank of Canada reaffirmed an “outperform” rating and set a $40.00 target price on shares of NewAmsterdam Pharma in a report on Friday, January 24th. Scotiabank raised their price objective on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a “sector outperform” rating in a research note on Thursday, February 27th. UBS Group set a $41.00 target price on NewAmsterdam Pharma in a report on Monday, March 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $48.00 target price on shares of NewAmsterdam Pharma in a research report on Tuesday, January 14th. Finally, Needham & Company LLC dropped their price target on NewAmsterdam Pharma from $46.00 to $42.00 and set a “buy” rating on the stock in a research report on Thursday, February 27th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $43.33.

Insider Buying and Selling at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, Director James N. Topper bought 4,005 shares of the company’s stock in a transaction that occurred on Tuesday, March 4th. The shares were acquired at an average cost of $21.02 per share, for a total transaction of $84,185.10. Following the acquisition, the director now directly owns 3,012,434 shares of the company’s stock, valued at $63,321,362.68. This trade represents a 0.13 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Nap B.V. Forgrowth sold 29,846 shares of the firm’s stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $25.54, for a total transaction of $762,266.84. Following the sale, the insider now owns 10,656,172 shares of the company’s stock, valued at $272,158,632.88. The trade was a 0.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 19.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On NewAmsterdam Pharma

Several institutional investors have recently bought and sold shares of NAMS. GF Fund Management CO. LTD. acquired a new position in NewAmsterdam Pharma during the fourth quarter valued at approximately $50,000. National Bank of Canada FI acquired a new position in shares of NewAmsterdam Pharma during the fourth quarter valued at about $51,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of NewAmsterdam Pharma in the fourth quarter valued at about $80,000. Quarry LP increased its stake in NewAmsterdam Pharma by 2,469.2% during the third quarter. Quarry LP now owns 6,500 shares of the company’s stock valued at $108,000 after acquiring an additional 6,247 shares during the period. Finally, Barclays PLC raised its holdings in NewAmsterdam Pharma by 1,813.4% in the 3rd quarter. Barclays PLC now owns 7,596 shares of the company’s stock valued at $126,000 after acquiring an additional 7,199 shares in the last quarter. 89.89% of the stock is currently owned by institutional investors.

NewAmsterdam Pharma Trading Down 2.9 %

NAMS stock traded down $0.65 during midday trading on Friday, reaching $21.76. The company had a trading volume of 690,361 shares, compared to its average volume of 532,561. NewAmsterdam Pharma has a 1 year low of $15.19 and a 1 year high of $27.29. The company has a 50 day moving average of $21.66 and a two-hundred day moving average of $21.27. The company has a market capitalization of $2.39 billion, a P/E ratio of -8.37 and a beta of -0.04.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The company had revenue of $12.77 million during the quarter, compared to analyst estimates of $3.30 million. On average, sell-side analysts anticipate that NewAmsterdam Pharma will post -1.75 earnings per share for the current year.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.